CUE Stock - Cue Biopharma, Inc.
Unlock GoAI Insights for CUE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.29M | $5.49M | $1.25M | $14.94M | $3.15M |
| Gross Profit | $9.29M | $-32,607,000 | $1.25M | $16.72M | $-30,391,379 |
| Gross Margin | 100.0% | -593.9% | 100.0% | 111.9% | -963.5% |
| Operating Income | $-41,500,000 | $-52,149,000 | $-53,225,000 | $-43,712,073 | $-45,042,585 |
| Net Income | $-40,674,000 | $-50,733,000 | $-53,010,000 | $-44,161,175 | $-44,784,921 |
| Net Margin | -438.0% | -924.1% | -4257.8% | -295.6% | -1419.8% |
| EPS | $-0.72 | $-1.11 | $-1.49 | $-1.41 | $-1.56 |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 13th 2024 | Jefferies | Initiation | Buy | $6 |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $10 |
| November 21st 2022 | Piper Sandler | Initiation | Overweight | $7 |
Earnings History & Surprises
CUEEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.10 | $-0.07 | +30.0% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.13 | $-0.09 | +30.8% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.14 | $-0.17 | -21.4% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.29 | $-0.20 | +31.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.30 | $-0.25 | +16.7% | ✓ BEAT |
Q2 2024 | Apr 8, 2024 | $-0.28 | $-0.28 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $-0.30 | $-0.24 | +20.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.30 | $-0.29 | +3.3% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.33 | $-0.29 | +12.1% | ✓ BEAT |
Q1 2023 | Mar 21, 2023 | $-0.32 | $-0.37 | -15.6% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.38 | $-0.31 | +18.4% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.43 | $-0.44 | -2.3% | ✗ MISS |
Q1 2022 | Mar 16, 2022 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.39 | $-0.41 | -5.1% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.42 | $-0.33 | +21.4% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.37 | $-0.41 | -10.8% | ✗ MISS |
Latest News
Cue Biopharma shares are trading lower after the company announced it price its $10 million public offering of 35.7 million shares and warrants at $0.28 per share and warrant.
📉 NegativeCue Biopharma prices $10M underwritten public offering; shares down
📉 NegativeCue Biopharma Prices $10M Public Offering Of 35.7M Shares And Warrants At $0.28; Closing Expected December 22
📉 NegativeCue Biopharma shares are trading lower after the company announced a proposed public offering.
📉 NegativeCue Biopharma Announces Proposed Public Offering; Size Not Disclosed
➖ NeutralImmunoScape Announces Exclusive In-Licensing Deal With Cue Biopharma To Lead Development Of Distinct Therapies To Attack Solid Tumor Cancers
📈 PositiveCue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate
➖ NeutralCue Biopharma And ImmunoScape Announce Exclusive Collaboration And License Agreement; ImmunoScape To Cevelop A Seed-and-Boost Immunotherapy Combining Cue Biopharma's CUE-100 With ImmunoScape's TCRs
📈 PositiveLUCID CAPITAL MARKETS Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $4
📈 PositiveCue Biopharma stock falls after pricing capital raise of $20M via securities offering
📉 NegativeFrequently Asked Questions about CUE
What is CUE's current stock price?
What is the analyst price target for CUE?
What sector is Cue Biopharma, Inc. in?
What is CUE's market cap?
Does CUE pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CUE for comparison